Overview

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Helsinn Healthcare SA

Treatments:

Palonosetron